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Selective Antimicrobial Modulation of the Intestinal Flora of Patients with 
Acute Nonlymphocytic Leukemia: A Double-Blind, Placebo-Controlled Study
H. F. L. Guiot, P. J. van den Broek, From the Isolation Ward, J. A . Cohen Institute o f
J. W. M. van der Meer, and R. van Furth Radiopathology and Radiation Protection; and the
Department o f  Infectious Diseases, University Hospital,
Leiden, the Netherlands
Thirty-three patients with acute nonlymphocytic leukemia were studied during remis- 
sion-induction treatment in a double-blind, placebo-controlled, randomized study to 
ascertain the effect on the incidence of infection of an oral regimen of selective antimi­
crobial modulation (SAM). A decrease in the number of major acquired infections was 
observed: three infections occurred in 16 patients receiving the SAM regimen compared 
with eight infections in 17 patients given the placebo. The reduction of infection was 
correlated with a reduction of fever, with a reduction of the frequency of administra­
tion of antimicrobial agents for the treatment of infection, and with the selective elimi­
nation of aerobic and facultative anaerobic gram-negative rods from the digestive tract.
Substantial unfavorable side effects were not observed.
Patients with acute leukemia experience prolonged 
periods of neutropenia due to their disease or its 
treatment. For this reason they often develop seri­
ous infectious complications. Although antibiotic 
therapy has improved in recent years and the fatal­
ity rate has been decreased, infection is still an im­
portant cause of morbidity and mortality in pa­
tients treated for acute leukemia [1]. Prevention of 
infections by protective isolation and supression 
of intestinal flora probably reduces a part of the 
infectious problems.
Since 1976, infection prevention in the isolation 
ward of our hospital has consisted of protective 
isolation (laminar airflow rooms and food with a 
low bacterial level) and selective elimination of po­
tentially pathogenic aerobic and facultative an­
aerobic bacteria from the skin and mucosal sur­
faces [2]. The combination of antimicrobial agents 
chosen for administration to the patients at risk 
has only limited or no activity against anaerobic 
bacteria [3]. The objective goal of this regimen of
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selective antimicrobial modulation (SAM) [3] (re­
ferred to as partial antibiotic decontamination 
elsewhere [2]) is to preserve colonization resistance 
[3, 4]. Colonization resistance refers to the resis­
tance that microorganisms must overcome before 
they can colonize body surfaces [5]. The SAM ap­
proach seemed justified because aerobic bacteria 
are frequently involved in infectious complica­
tions in neutropenic patients, whereas the an­
aerobic bacteria seem to be relatively harmless [6].
From a previous study it was concluded that the 
SAM regimen prevents major infections in pa­
tients with severe bone-marrow failure [3], but it 
remained uncertain whether the SAM regimen 
would have the same favorable effect in hospitals 
with restricted facilities for protective isolation 
and bacteriologic control. The present study was 
performed to determine whether selective elimina­
tion of aerobic and facultative anaerobic gram- 
negative bacteria from the intestinal tract would 
reduce the number of infectious complications 
without the use of other sophisticated preventive 
measures.
In contrast to the previous study [3], no local 
antimicrobial treatment was applied to the oral 
cavity and skin, the patients were not isolated in 
laminar airflow rooms but were nursed in single­
bed rooms, and patients were given conventional 
hospital food with some restriction of heavily con­
taminated food. Moreover, the attending physi­
cians were not told the results of surveillance cul­
tures of the patients.
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The present report describes the results of this 
double-blind, placebo-controlled study on the ef­
ficacy of the SAM regimen in patients with acute 
nonlymphocytic leukemia who were nursed in 
conventional single-bed rooms.
Patients and Methods
Patient selection and randomization. All adult 
patients admitted between September 1977 and 
October 1981 with acute nonlymphocytic leu­
kemia, and for whom a single-bed room was avail­
able, were eligible for the study. After informed 
consent was obtained, the patients were randomly 
assigned to receive the SAM regimen or placebo. 
Infection, fever, or other clinical complications 
present at the time of randomization did not ex­
clude the patients from the study.
After randomization the patients were subjected 
to conventional physical and base-line bactério­
logie examination. Simultaneously, or within a 
few days after the initial administration of the 
SAM regimen or placebo, therapy for leukemia 
was begun. Only patients who had received the 
SAM regimen for at least one week and patients 
with granulocytopenia (granulocyte count, <500/ 
m m 3) for at least one week were evaluated.
Infection prevention. Patients receiving SAM 
or placebo were nursed in conventional single-bed 
rooms. Persons entering a patient’s room were re­
quired to wash their hands with povidone-iodine 
soap and to wear a mask and a gown that was only 
used in that room and that was replaced with a 
clean one at least once a day. The patients were 
not permitted to leave the room, except for exam­
ination elsewhere in the hospital or for a few days’ 
stay at home (at most, for seven days) between 
two courses of cytostatic therapy. During the lat­
ter period the SAM regimen or placebo was con­
tinued at home. Both patient groups were given 
conventional hospital food with some restrictions 
concerning food assumed to be heavily contam ­
inated (for example, raw meat and fish and deep- 
fried food from snack bars).
The SAM regimen consisted of four capsules 
(size, 6 x 1 8  mm) containing a mixture of neomy­
cin, polymyxin B, and amphotericin B, given four 
times daily, and two capsules (size, 8 x  24 mm) 
containing nalidixic acid, given twice daily. The 
total dosage o f these prophylactic antimicrobial 
drugs administered daily was 1 g of neomycin, 1 g
of amphotericin B, 2 g of nalidixic acid (in the pre­
vious study [3], 4 g was given), and 400 mg of 
polymyxin B. The placebo consisted of capsules 
containing starch that were matched for size and 
color. All patients were treated locally in the nose 
with a cream containing 0.5970 neomycin and 0.1 % 
chlorhexidine hydrochloride to prevent carriage of 
Staphylococcus aureus. No other topical anti­
septics were used.
The patients started their prophylactic regimen 
as soon as the base-line bacteriologie cultures had 
been obtained. If the clinical condition deteri­
orated because of the disease or antileukemic 
treatment, the patients were stimulated to swallow 
all of the capsules. When this was not possible, 
they were allowed to use fewer capsules during 
periods of chemotherapy. The capsules were swal­
lowed whole, or they were opened and the con­
tents were suspended in tea or another drink, 
which the patients drank during or after meals.
Prophylaxis or placebo was terminated and no 
further cytostatic therapy was given as soon as 
granulocyte counts exceeded 500/m m 3 or if the at­
tending physicians judged continuation of pro­
phylaxis or placebo to be useless for clinical or 
psychological reasons.
Bacteriologie investigations. Bacteriologie sur­
veillance cultures were obtained once a week and 
included cultures of urine, feces, and swabs taken 
from the nasopharyngeal, oropharyngeal, geni­
tourinary, and perineal regions. The semiquantita- 
tive and qualitative bacteriologie techniques have 
been previously described [2]. The results of these 
surveillance cultures were not provided to the at­
tending clinical staff. Bacteriologie examination 
for diagnostic purposes was performed when the 
clinical condition suggested bacterial infection.
M anagement o f  infection. In all patients, sys­
temic antibiotic treatment was not instituted until 
infection was seriously suspected or proven. The 
choice of antibiotics was governed by the site of 
the infection and the suspected causative micro­
organisms. If the causative infectious agents were 
unknown, therapy almost always consisted of 
combinations of two antibiotics given iv. When­
ever possible, antibiotic therapy was adjusted on 
the basis of the results of bacteriologie investiga­
tion.
Definition o f  infections. Infections were di­
vided into bacterial, fungal, viral, and protozoan 
infections. The bacterial and fungal infections,
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whether microbiologically proven or not, were di­
vided into minor infections (clinically manifested 
infections of the skin or mucosa without extension 
to deep tissue, such as stomatitis, gingivitis, or 
pharyngitis) and major infections (infections with 
extension to the blood, deep tissues, or organs, 
such as pneumonia or pyelonephritis). Infections 
were called doubtful if the diagnostic procedures 
did not give conclusive results and the patient’s 
clinical condition (fever) was the only suggestion 
of infection and if no response to antimicrobial 
therapy was observed.
Acquired infections were defined as infections 
showing their first clinical signs after the first 
week of the SAM regimen or placebo.
Fever. Each day on which a patient’s axillary 
body temperature at least once was ^38 C was de­
fined as a day with fever. An axillary body tem­
perature of >39 C was considered to be high fever.
Granulocytopenic episodes. A period of two 
or more successive days with granulocyte counts 
of <500/m m 3 was defined as a granulocytopenic 
period.
Therapy fo r  hematologic disease. All patients 
were treated with one or two remission-induction 
regimens. The LAM V treatment protocol (no. 
06781) of the European Organization for Research 
on Treatment of Cancer (Zurich) consists of 1 mg 
of vincristine/m2 o f body surface area on day 1, 
50 mg of doxorubicin/m2 on day 2, and 80 mg of 
cytarabine/m2 twice daily on days 3-9. The COAP 
protocol, which is less cardiotoxic, consists of 1.4 
mg of vincristine/m2 on day 1, 100 mg each of 
cyclophosphamide and cytarabine/m2 on days 
1-5, and 40 mg of prednisone/m2 on days 1-5. In 
the present study, all patients received the LAM V 
treatment protocol except two, one in each group, 
who received the COAP protocol because of their 
advanced age.
Questionnaires. The patients were given a 
multiple-choice questionnaire after receiving the 
SAM regimen or placebo for three or more weeks. 
The questions concerned appetite and nausea.
Statistical evaluation. Statistical evaluation of 
differences was determined by Wilcoxon’s two- 
sample test.
Results
Comparability o f  the randomized groups. For­
ty-two patients were randomized; 21 patients were
allocated to receive the prophylactic regimen 
(SAM), and the other 21 patients received place­
bo. Five patients in the SAM group were excluded 
from the study because the period during which 
they received the SAM regimen or the period dur­
ing which they were at risk was too short for eval­
uation (one week or less). In these patients pro­
phylaxis was terminated on psychological grounds 
in one patient, because of a clinical condition too 
poor to permit cooperation in two patients, and 
because the granulocytopenic period was too short 
(fewer than seven days with granulocyte counts of 
<500/m m 3) in the other two patients. In the con­
trol group four patients were excluded: one be­
cause of psychological reasons, one because the 
code was broken as the result of hearing loss 
(which was suspected to be due to neomycin), one 
because his poor clinical condition made it impos­
sible for him to swallow the placebo for at least 
one week, and one because the granulocytopenic 
period lasted for fewer than seven days. The re­
maining patients, 16 in the SAM group and 17 in 
the placebo group, were comparable as to age, di­
agnosis, antileukemic therapy (table 1), and clin­
ical condition at the time of randomization (table
2). No significant differences in the response to 
hematologic treatment and the number of granu­
locytopenic days, platelet transfusions, and days
Table 1. Clinical characteristics of patients with acute 
nonlymphocytic leukemia who received a regimen of 
selective antimicrobial modulation (SAM) or placebo.
Clinical characteristic
SAM 
group (16)
Placebo 
group (17)
Mean age in years (range) 49.4 (23-71) 48.5 (18-69)
Malerfemale ratio 7:9 7:10
Mean no. of days SAM regimen
or placebo was given 50.4 45.5
Diagnosis
Acute myelogenous leukemia 11 10
Acute myelomonocytic
leukemia 4 7
Acute undifferentiated
leukemia 1 0
Therapy
LAM V protocol* 15 16
COAP protocol* 1 1
First remission induction 13 14
Second remission induction 2 3
Third remission induction 1 0
NOTE. Data are nos. of patients unless otherwise indicated. 
* Described in Materials and Methods.
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Table 2. Response to antileukemic therapy, hematologic data, and clinical course in patients with acute nonlym- 
phocytic leukemia who received a regimen of selective antimicrobial modulation (SAM) or placebo.
Factor SAM group (16) Placebo group (17)
Response to therapy (no. of patients)
Complete remission 8 8
Partial remission 3 3
No remission
Discharged, clinical condition good 3 3
Discharged, clinical condition poor 2 2
Died of bleeding and infection 0 1
Mean no. (range) of patient-days with granulocyte counts of
<500/mm3* 35.1 (7-126) 28.5 (13-51)
< 100/m m 3* 14.2 (0-31) 13.2 (0-24)
Platelet transfusions during days of SAM regimen or placebo
(no. of transfusions per 100 days) 18.6 22.9
* Differences between the SAM and placebo groups are not statistically significant (P  > 0.60 by Wilcoxon’s two-sample test).
of the SAM regimen or placebo were observed be­
tween the two groups (table 2).
Efficacy o f  antimicrobial prophylaxis. Infec­
tion. It was assumed that the SAM regimen 
takes at least one week to become effective for the 
prevention of infection. Therefore, the first week 
of prophylaxis has been evaluated separately from 
the remaining period of the SAM regimen. In the 
first week, five of 16 SAM patients became in­
fected or were already infected, and two SAM pa­
tients had fevers with unknown origins (table 3). 
One of these infections was a rectal abscess that, 
after drainage, was found to be caused by Esche­
richia coli and Enterobacter cloacae. The other in­
fections were minor local infections in the oropha­
ryngeal region. Seven of the 17 patients who re­
ceived placebo became infected or were infected in 
the first week. One of these patients had septi-
Table 3. Clinical condition of patients with acute 
nonlymphocytic leukemia during the first week of selec­
tive antimicrobial modulation (SAM) or placebo.
Clinical condition
SAM 
group (16)
Placebo 
group (17)
Minor infections
Nasopharyngeal or oropharyngeal
infection 4 3
Diverticulitis 0 1
Urinary tract infection 0 1
Major infections
Septicemia 0 1
Rectal infection 1 1
Fever of unknown origin 2 0
NOTE. Data are nos. of patients.
cemia due to E. coli, one had a rectal infiltrate, 
and one patient had a diverticulitis. The others 
had minor local infections in the oropharyngeal 
region (gingivitis, stomatitis, and pharyngitis). 
The differences concerning infectious complica­
tions between the two groups of patients during 
the first week are not significant (P  = 0.95).
Table 4. Infections acquired by patients with acute 
nonlymphocytic leukemia after the first week of selec­
tive antimicrobial modulation (SAM) or placebo.
SAM Placebo
Factor group (16) group (17)
No. of patients with major
infections due to gram-
negative organisms 1* 7*
Total no. of clinically or
bacteriologically docu­
mented infections 5 11
No. of major infections 3 t 8t
Septicemia due to gram-
negative bacteriaî 1 7
Septicemia due to Strepto­
coccus pneumoniae 1 0
Pneumonia due to
Legionella pneumophila 0 1
Rectal infiltrate 1 0
No. of minor infections 2 3
Nasopharyngeal or oro­
pharyngeal infection 2 2
Urinary tract infection 0 1
Doubtful infections 3 3
* P  = 0.05 by Wilcoxon’s two-sample test, 
t  P  = 0.05 by Wilcoxon’s two-sample test.
' t  Gram-negative bacteria involved were Enterobacter cloacae 
for SAM patients and Pseudomonas aeruginosa, Escherichia coli, 
and Klebsiella pneumoniae for patients receiving placebo.
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Table 5. Antimicrobial therapy in patients with acute 
nonlymphocytic leukemia who received a regimen of 
selective antimicrobial modulation (SAM) or placebo.
SAM group (16) Placebo group (17)
Antimicrobial
agent
No. of 
patients
Days of 
therapy*
No. of 
patients
Days of 
therapy*
Aminoglycoside^ 6 7 (2-41) 8 14 (2-19)
Cephalosporint 3 3 (1-4) 8 8.5 (3-24)
Penicillin^ 10 9.5 (3-34) 8 7.5 (3-14)
Trimethoprim-
sulfamethoxazole 4 11 (9-14) 3 14 (4-14)
Miscellaneous 5 11 (5-17) 9 11.5 (6-53)
No drug 3 •  • • 2 • • •
One drug 6 •  • • 1 •  •  •
Two or more drugs 7 •  • • 14 •  •  •
* Median no. of days (range) on which the indicated therapy 
was administered, 
t  Tobramycin in 12 patients and gentamicin in two patients, 
t  Cefamandole.
§ Penicillin G in 13 patients, cloxacillin in four patients, and 
ampicillin in one patient.
Although no differences were shown in the first 
week of prophylactic treatment, a decrease (P  
= 0.05) in the number of acquired major infections 
was observed in the SAM patients during the re­
maining period compared to the patients receiving 
placebo (table 4). Two of the three m ajor infec­
tions acquired by the SAM patients were caused 
by microorganisms that are intrinsically insensi­
tive to the SAM regimen —septicemia due to 
Streptococcus pneumoniae  and a rectal infiltrate 
probably caused by anaerobic bacteria and Strep­
tococcus faecalis. In the third patient, septicemia 
with E. cloacae occurred. This infection was con­
sidered to be of exogenous origin —a secondarily 
infected herpes labialis lesion. Among the controls 
there were seven cases of septicemia due to gram- 
negative organisms, most of which probably orig­
inated from the oropharyngeal or rectal regions; 
one of these patients also developed pneumonia 
caused by Legionella pneumophila.
No differences were found between the SAM 
group and the placebo group with respect to local 
and doubtful infection. Evidence of viral infection 
was obtained in two SAM patients; those infec­
tions were due to herpes simplex virus, one of 
which was associated with a secondary bacterial 
infection as mentioned above. In the patients 
given placebo, lesions due to herpes simplex virus 
became secondarily infected with Klebsiella pneu­
moniae.
Antibiotic use. The reduction of infectious 
complications in the SAM group was associated 
with a reduction of the use of both aminoglyco­
sides and cephalosporins; the use of penicillin, tri- 
methoprim-sulfamethoxazole, and other antibi­
otics was not lower than that in the placebo group 
(table 5). Aminoglycosides were administered for 
the treatment of an assumed infection in six SAM 
patients, and retrospective analysis reveals that 
this had not been necessary in at least four of 
them.
Fever. Although the reduction of the inci­
dence of major infection in the SAM group in 
comparison to the placebo group is obvious, the 
effect on fever is less pronounced. In the SAM 
group, fever occurred on a mean of 9.5 days 
(19%) during the mean prophylaxis period of ~50  
days, whereas fever occurred on 14 days (31%) 
during the mean prophylaxis period of 45 days for 
the patients given the placebo. To find out 
whether this difference was associated with a 
reduced incidence of infection, only days with 
fever during the risk period (granulocyte counts, 
<500/m m 3) were considered for statistical evalua­
tion. Single days during which a patient’s fever 
was probably not associated with infection (total, 
nine days for the SAM group and 26 days for the 
placebo group) and days with fever occurring after 
the termination o f prophylaxis or placebo were 
not included.
In the SAM group, 22 granulocytopenic epi­
sodes occurred, of which eight were not associated 
with fever; in the control group, 20 granulocy­
topenic episodes occurred, of which seven were 
not associated with fever. The mean duration of 
the granulocytopenic episodes without fever was 
about 18 days for both groups. The duration of 
the other granulocytopenic episodes —those that 
were associated with fever —was longer, am ount­
ing to a mean o f 28 and 26 days for the SAM and 
placebo groups, respectively (figure 1). In the 
SAM group, fever occurred during about 11 
(41%) of these days, as compared with 13.5 (52%) 
days for the control group. If only days with high 
fever (axillary temperature, >39 C) are taken into 
account, the difference in the mean number of 
days with fever (four and 6.5 days for the SAM 
and control groups, respectively) is significant (P  
= 0.05).
Bacteriologie evaluation. The results obtained 
from the cultures of fecal samples obtained once
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Figure 1. Mean duration of granulocytopenic episodes 
associated with fever in patients with acute nonlympho- 
cytic leukemia who received a regimen of selective antimi­
crobial modulation (SAM) or placebo. The bars represent­
ing the no. of days per granulocytopenic episode (left) 
are divided into days with granulocyte counts of 100- 
500/mm3 and days with counts of < 100/mm3. The bars 
representing the no. of granulocytopenic days with fever 
per granulocytopenic episode (right) are divided into days 
with an axillary body temperature of 38-39 C and days 
with a temperature of >39 C. The nos. of granulocyto­
penic episodes evaluated in each group are indicated 
above the bars.
a week are shown in figure 2. On the first day of 
prophylaxis, aerobic gram-negative rods were cul­
tured from almost all fecal samples. After the first 
week the aerobic gram-negative rods had been 
eliminated from the stools of most SAM patients, 
and the fecal cultures only incidentally were found 
to contain aerobic gram-negative bacteria; in con­
trast, almost all fecal samples from the placebo 
group contained gram-negative bacteria. The 
gram-negative bacteria shown in the fecal samples 
of SAM patients were sensitive to the antimicro­
bial drugs in the SAM regimen; they were tran­
sient, or, if they persisted temporarily, the failure 
was associated with an interruption of the intake 
of the SAM regimen. Although the antibacterial 
activity of the SAM regimen was solely localized 
in the intestines, a reduction of aerobic gram-neg­
ative rods also occurred in the oral cavity and the 
genitourinary region and on the skin. E. coli was 
cultured from swabs taken from these locations 
(figure 3) in ^ 2 5 %  of the swabs in the SAM group 
and in 95% of the swabs in the placebo group. For 
Klebsiella species, the percentages of positive 
swabs were 10% in the SAM group and 20% in the 
placebo group, and for other Enterobacteriaceae, 
5% and 40%, respectively. Pseudomonas aeru­
ginosa was cultured from ~ 1% of the swabs in the 
SAM group and in 15% of the swabs in the 
placebo group. As in the cultures o f the fecal 
samples, these gram-negative rods were often 
transient in the SAM group in contrast to the 
placebo group.
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Figure 2. Percentage of cultures 
with aerobic and facultative anaerobic 
gram-negative rods cultured from 
stool samples of patients with acute 
nonlymphocytic leukemia who re­
ceived a regimen of ( • )  selective anti­
microbial modulation (SAM) or (O) 
placebo. The nos. of samples cultured 
are indicated at the top of the figure.
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Figure 3. Percentages of aerobic 
and facultative anaerobic gram-nega­
tive rods cultured from swabs of the 
oral cavity, genitourinary region, and 
skin of patients with acute nonlym- 
phocytic leukemia who received a regi­
men of (solid figures) selective anti­
microbial modulation (SAM) or (open 
symbols) placebo. The nos. of samples 
cultured are indicated at the top of the 
figure.
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Complications and compliance. With the ex­
ception o f  one case, none o f  the data  indicated 
that either more or fewer im portan t  complications 
had to be attributed to the SAM regimen. This 
single exception concerned a patient with a hyper­
sensitivity reaction, probably to nalidixic acid. 
Comparison o f  the reasons for termination of  the 
SAM regimen or placebo (table 6) reveals no dif­
ferences between the two groups in this respect.
Weeks on prophylaxis
Nausea occurred mainly during antileukemic 
treatment and was often ascribed to the intake of 
the capsules whether they contained the SAM regi­
men or placebo. Appetite was decreased similarly 
in the two groups, a result which is consistent with 
the loss o f  body weight because no significant dif­
ferences were observed between the two groups in 
the loss o f  body weight (P = 0.74). A lthough the 
patients did not report in the questionnaires that
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Table 6. Side effects and compliance of patients with acute nonlymphocytic leukemia who received a regimen of 
selective antimicrobial modulation (SAM) or placebo.
Factor SAM group (16) Placebo group (17)
Skin rash or drug fever r 5* 9
Hearing losst 2 2
Nausea
Vomitingî 8 8
Questionnaire answers (yes/no)
Decrease of appetite 4/5 7/5
Nausea 4/5 3/9
Mean loss of body weight (kg) during evaluation period 2.35§ 1.48§
No. of patient-days on which SAM regimen or placebo was
administered 50.4 45.5
Reasons for termination of SAM regimen or placebo
Full or partial hematologic recovery 9 8
Partial recovery but patient refused
Continuation of prophylaxis 2 1
Continuation of barrier nursing 2 3
No response to antileukemic therapy 3 5
NOTE. Data are nos. of patients unless otherwise indicated.
* One case was probably due to nalidixic acid, 
t  Audiographically documented.
t  Recorded in the patients’ observation chart by the attending staff. 
§ P  = 0.74 by Wilcoxon’s two-sample test.
nausea was associated with the SAM regimen, 
their aversion to swallowing the capsules in the 
SAM regimen was observed by the attending staff 
during courses o f  antileukemic therapy.
Discussion
In this randomized, double-blind, placebo-con­
trolled study, we evaluated the efficacy of the 
SAM regimen on the rate of  infections during re- 
mission-induction treatment in patients with acute 
nonlymphocytic leukemia. The SAM regimen was 
chosen because it selectively eliminates aerobic 
gram-negative bacteria from the intestinal tract 
and it does not affect the anaerobic flora to a mea­
surable degree [3]. The purpose of  the preserva­
tion of  the anaerobic intestinal flora is to retain 
the antagonistic activity of  the anaerobes against 
potentially pathogenic aerobic bacteria [3, 4].
As a divergence from a previous study on SAM
[3], a number of  simplifications were introduced. 
In the present study the patients were convention­
ally isolated in single-bed rooms instead o f  lami­
nar airflow rooms, conventional food was given 
instead o f  food with a low bacterial level, local an ­
tiseptic treatment was not applied, and the a t tend­
ing physicians were not told the results of  the bac-
teriologic surveillance cultures. These simplifica­
tions were introduced to evaluate the feasibility of 
SAM in a conventional hospital environment.
The patients assigned to the SAM group were 
comparable to the patients who received placebo 
in every respect. A significant reduction in the 
number of  patients with acquired major  infections 
due to gram-negative organisms was shown in the 
SAM group. This reduction o f  infection was asso­
ciated with a reduction of  fever and a reduction in 
the use o f  aminoglycosides and cephalosporins in 
the SAM group in comparison with the placebo 
group. However, this reduction of  fever is not 
substantial, which suggests that many noninfec- 
tious factors are involved in the fever o f  patients 
treated for acute myelogenous leukemia. The re­
duction of  the number of  days with high fever 
(>39 C) in the SAM group is significant, a result 
which correlates with the observed reduction of 
m ajor  infectious complications. Almost the same 
results were obtained in a previous study [7]. O b­
jections to the method o f  evaluation o f  the occur­
rence of  fever, based on the possibility o f  bias in­
troduced by exclusion o f  fever continuing after 
termination o f  SAM or placebo, are refutable, 
since fever continued in one of  three SAM patients 
and in six o f  seven patients who received placebo,
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all o f  whom continued to be granulocytopenic a f­
ter termination of the SAM regimen or placebo 
capsules.
As a consequence of  the limited isolation mea­
sures, contamination of the oral cavity, skin, and 
genitourinary region was frequently observed in 
the present study. The use o f  conventional food 
and the omission of  topical antiseptics were p rob­
ably responsible for these contaminations. The ex­
ogenous bacteria were transient in most SAM pa­
tients, whereas they persisted longer in the placebo 
group. Because of  the prophylactic regimen, only 
a small proportion of  the fecal cultures of  SAM 
patients showed aerobic gram-negative rods com­
pared with those o f  the placebo group. It is re­
markable that the elimination of  aerobic gram- 
negative rods from the intestines also resulted in a 
reduction o f  these bacteria in the oral cavity, the 
genitourinary region, and on the skin.
The lack o f  adequate isolation measures is only 
reflected by infection with herpes simplex virus in 
one SAM patient. In this patient, septicemia with 
E. cloacae could probably have been prevented by 
better isolation. Routine bacteriologic surveillance 
cultures in SAM patients would probably con­
tribute to the choice of  adequate antimicrobial 
therapy in case o f  infection and to the mainte­
nance o f  the quality of  prophylaxis. However, in 
the present study antimicrobial drugs were p rob­
ably given more often than really needed in the 
SAM group because o f  the inaccessibility of  the 
results o f  surveillance cultures.
In general, tolerance to the ingestion o f  the 
SAM regimen was reasonable. O f  course, most of  
the patients did not like having to swallow the cap­
sules and tablets four times a day, but objective 
observations (patients’ observation cards and 
questionnaires) did not show substantial differ­
ences between tolerance in the two groups. No 
signs o f  toxicity, diarrhea, or other complications 
attributable to the SAM regimen were observed.
It can be concluded that in general the results of  
the present study confirm the findings o f  the pre­
vious study on SAM [3], indicating that m ajor  in­
fections with gram-negative microorganisms can 
be prevented by SAM. The prophylactic regimen 
mainly reduces morbidity; a favorable effect on 
remission rate and survival was not found for the 
small number of  patients in this study.
The question o f  whether the SAM regimen is su­
perior or inferior to other regimens for selective
suppression of  intestinal flora cannot be an­
swered. The reports on the prophylactic use of  tri- 
methoprim-sulfamethoxazole, which has been 
claimed to be a potential method for selective sup­
pression of  intestinal flora, suggests a favorable 
effect in infection prevention [8, 9] and excellent 
tolerance. On the other hand, prolonged granulo­
cytopenia [8] and selection of  resistant strains 
have been reported [8, 10]. The chance of  the se­
lection of resistant strains against trimethoprim- 
sulfamethoxazole and the favorable experience 
with SAM have been decisive factors in our de­
cision to use the SAM regimen for prophylaxis in 
our hospital in the future and to limit the use of 
trimethoprim-sulfamethoxazole for the treatment 
of  infection only.
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